Dernières nouvelles pour Edwards Lifesciences (NYSE:EW) Stock

EDWARDS LIFESCIENCES CORP

Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences Corp

iShares MSCI Australia Index Fund

East West Bancorp Inc

EAST WEST BANKING CORP by EAST WEST BANKING CORPORATION

iShares MSCI Canada Index Fund

ENERGY WORLD CORP LTD by Energy World Corp. Ltd.

Energy World Corp Ltd

European Wax Center, Inc. - Class A Common Stock

European Wax Center Inc

iShares Inc iShares MSCI Sweden ETF

Global X Funds Emerging Mkts Internet & E- Commerce ETF (New)

iShares MSCI Germany Index Fund

EAT WELL INVT GROUP INC by Eat Well Investment Group Inc.

Eat Well Investment Group Inc

iShares Trust MSCI Germany Small-Cap ETF

iShares MSCI Hong Kong Index Fund

iShares Inc iShares MSCI Italy ETF

EDINBURGH WORLDWIDE INVES by Edinburgh Worldwide Investment Trust plc

iShares MSCI Japan Index Fund

iShares MSCI Japan Value ETF

iShares Inc iShares MSCI Belgium ETF

EARTHWORKS ENTMT NEW by Earthworks Entertainment, Inc.

Earthworks Entertainment Inc

iShares Inc iShares MSCI Switzerland ETF

EWELLNESS HEALTHCARE CORP by eWellness Healthcare Corp

eWellness Healthcare Corp

Merion Inc

iShares MSCI Malaysia Index Fund

iShares MSCI Netherlands Index Fund

iShares Inc iShares MSCI Austria ETF

EASTWOOD BIO-MED CDA INC by Eastwood Bio-Med CDA Inc.

iShares Inc iShares MSCI Spain ETF

EMERGING WORLD PHARMA INC by Emerging World Pharma, Inc.

Emerging World Pharma Inc

EAST WEST PETE ORD by East West Petroleum Corp.

East West Petroleum Corp

iShares MSCI France Index Fund

EWORLD COMPANIES INC by eWorld Companies, Inc.

eWorld Companies Inc

iShares Inc iShares MSCI Singapore ETF

EWSB Bancorp Inc

iShares Inc iShares MSCI Taiwan ETF

Energy Web - United States Dollar

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics Inc

iShares MSCI United Kingdom ETF

iShares MSCI United Kingdom Small Cap ETF

ProShares UltraShort MSCI Japan

iShares Inc iShares MSCI Mexico ETF

SPDR S&P Emerging Markets Small Cap ETF

iShares Inc iShares MSCI South Korea ETF

iShares Inc iShares MSCI Brazil ETF

iShares MSCI Brazil Small-Cap ETF

President Donald Trump announced tougher-than-anticipated tariffs on Wednesday, but there are some <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">notable exemptions</a>.
Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff <a href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" target="_blank" rel="noreferrer noopener">on pharmaceutical imports</a>. 
&#8220;The United States can no longer produce enough antibiotics to treat our sick,&#8221; Trump said Wednesday. &#8220;We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn&#8217;t be able to do it.&#8221;
The biopharma industry has historically been shielded from tariffs, including during Trump's first term. Investors had feared global tariffs could disrupt the sector, given its significant manufacturing presence in Europe. The Morningstar <a target="_blank" href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" rel="noreferrer noopener">report</a> says that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have resulted in a $20 billion cost to the industry, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592073/tariffs-could-shake-building-industry-homebuilders-plumbing-flooring-face-rising-costs" rel="noreferrer noopener">Tariffs Could Shake Building Industry: Homebuilders, Plumbing, Flooring Face Rising Costs</a>
Per the Morningstar report on Thursday, a future global tariff on pharmaceuticals remains a risk despite the exemption, potentially pressuring gross margins and long-term tax rates. Companies may need to adjust their manufacturing strategies, though large-cap biopharma firms are expected to maintain strong economic positions. Tariffs could drive near-term margin pressures and lead to long-term U.S. manufacturing investments.
However, new facilities would take years to gain approval, especially with ongoing FDA staff <a href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" target="_blank" rel="noreferrer noopener">reductions affecting inspections</a>. If U.S. manufacturing increases, corporate tax rates could rise closer to the current 21% rate &#8211; a level Trump aims to maintain through the Republican-controlled Congress.
However, the medical device industry has not been spared, with diabetes device makers appearing to be the hardest hit.
Diabetes device manufacturers, including Dexcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Insulet Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) are among the most affected.
Larger cardiac and orthopedic device makers, such as Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) and Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) have seen minimal share movement and are expected to shift manufacturing to mitigate tariff effects.
The report <a href="https://www.morningstar.com/stocks/medical-device-industry-swept-up-tariffs-diabetes-device-makers-bear-brunt" target="_blank" rel="noreferrer noopener">notes</a> that among diabetes device makers, Tandem Diabetes appears particularly vulnerable due to its reliance on foreign components and manufacturing, limiting its ability to shift production.
The sector could face further challenges if European competitors, such as Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) and Ypsomed, gain an advantage or if Europe imposes reciprocal tariffs, intensifying competitive pressures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44647281/fda-approves-amgens-uplizna-as-first-drug-for-chronic-immune-mediated-fibroinflammatory-disorder" target="_blank" rel="noreferrer noopener">FDA Approves Amgen&#8217;s Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Large Cap

News

Health Care

General

DXCM

PODD

RHHBY

TNDM

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>), adding that he likes the <a href="https://www.benzinga.com/quote/GRAL">stock a lot.</a>
Supporting his view, Morgan Stanley analyst Tejas Savant, on March 18, raised the price target on the stock from $16 to $20.
&#8220;That' like a dice roll,&#8221; Cramer said when asked about Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>). &#8220;That's a bridge too far for me.&#8221;
On the earnings front, Turkcell, on Feb. 27, posted an FY net profit of 23.52 billion Lira versus a year-ago profit of 18.13 billion Lira.
When asked about Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), he said, &#8220;I'm going to say buy half right now, and then if it breaks down below 53, then you can buy more.&#8221;
Keefe, Bruyette &amp; Woods analyst Vasundhara Govil, on March 18, upgraded Block from Market Perform to Outperform but lowered the price target from $87 to $80.
Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is a &#8220;reasonable&#8221; REIT, Cramer said.
On Feb. 28, Scotiabank analyst Nicholas Yulico maintained Healthpeak Properties with a Sector Outperform and lowered the price target from $24 to $23.
The Mad Money host said Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is doing &#8220;very, very well.&#8221;
As per the recent news, NTT DATA partnered with Rubrik on Monday for cybersecurity ransomware protection.
Cramer said Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is a hold and prefers Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) to Edwards Lifesciences.
On the earnings front, Edwards Lifesciences, on Feb. 11, posted better-than-expected quarterly earnings.
&#8220;We have to wait another quarter,&#8221; Cramer said when asked about Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>).
Wells Fargo analyst Anthony Trainor, on Wednesday, initiated coverage on Shake Shack with an Equal-Weight rating and announced a price target of $95.
TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) is an &#8220;interesting&#8221; company, Cramer said. &#8220;I'm not going to necessarily recommend it right here.&#8221;
Needham analyst Mike Matson reiterated TransMedics Group with a Hold rating on Wednesday.
&#8220;It's never been this cheap that I can recall,&#8221; Cramer said when asked about Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>). &#8220;Here's the problem, it's a data center stock.&#8221;
On March 5, UBS analyst David Vogt upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
Turkcell Iletisim Hizmetleri shares fell 2.3% to settle at $6.08 on Thursday.
GRAIL shares gained 0.7% to close at $28.58 during the session.
Arista Networks&#8217; shares fell 3.3% to settle at $78.96.
Shake Shack shares rose 0.3% to settle at $93.62.
TransMedics Group shares gained 0.2% to close at $70.44.
Rubrik shares fell 3.8% to settle at $66.00.
Edwards Lifesciences&#8217; shares rose 0.1% to close at $71.19.
Block shares fell 3.5% to settle at $56.99 on Thursday.
Healthpeak Properties shares fell 0.4% to close at $20.22.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44534563/netflix-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades">Netflix, Vertex Pharmaceuticals And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Mid Cap

Media

ANET

GRAL

RBRK

SHAK

TMDX

Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock

Edwards Lifesciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) short percent of float has fallen 28.92% since its last report. The company recently reported that it has 8.49 million shares sold short, which is 1.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Edwards Lifesciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742239820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Edwards Lifesciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Edwards Lifesciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Edwards Lifesciences's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Edwards Lifesciences?

Looking into the current session, Edwards Lifesciences Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares are trading at $71.65, after a 0.28% spike. Moreover, over the past month, the stock spiked by 0.45%, but in the past year, fell by 15.81%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740577514_0.png" alt="Past Year Chart" />

<h3>A Look at Edwards Lifesciences P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Edwards Lifesciences has a lower P/E than the aggregate P/E of 85.67 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740577514_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Edwards Lifesciences Inc's Price Over Earnings

Edwards Lifesciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) short percent of float has risen 10.97% since its last report. The company recently reported that it has 10.05 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Edwards Lifesciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739909722_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Edwards Lifesciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Edwards Lifesciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Edwards Lifesciences's Recent Short Interest

A significant insider transaction involving the exercise of company stock options was reported on February 13, by LESLIE HEISZ STONE, Director at Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), as per the latest SEC filing.
What Happened: The latest Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001099800/000122520825001709//Archives/edgar/data/1099800/000122520825001709/0001225208-25-001709-index.htm">U.S. Securities and Exchange Commission</a> uncovered STONE, Director at Edwards Lifesciences, exercising stock options for 5,739 shares of EW. The total transaction was valued at $179,534.
The latest update on Friday morning shows Edwards Lifesciences shares up by 0.79%, trading at $76.6. At this price, STONE's 5,739 shares are worth $179,534.
<h3>All You Need to Know About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
<h3>Financial Milestones: Edwards Lifesciences's Journey</h3>
Revenue Growth: Edwards Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 8.93%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 80.59%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Edwards Lifesciences's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 5.14.
</li>
</ul>
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 32.48 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 8.37 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 27.76, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001099800">Check Out The Full List Of Edwards Lifesciences's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Unloading: LESLIE HEISZ STONE Sells Options, Realizes $179K

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Overweight and raises the price target from $88 to $90.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $90

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $68 to $71.

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $71

On Tuesday, Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups.
Adjusted earnings per share came in at 59 cents, compared to <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analysts&#8217; estimate of 55 cents</a>.
Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640608/edwards-lifesciences-reports-fourth-quarter-results" rel="noreferrer noopener">in the fourth quarter</a>.
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $105 million for the quarter, supported by the strong adoption of the PASCAL repair system and EVOQUE replacement system. Full-year TMTT sales of $352 million marked a 77% year-over-year increase.
The Surgical segment reported sales of $244 million, up 6% year-over-year (+5% on constant currency), driven by robust adoption of RESILIA-based products.
The gross profit margin was 78.9%, or 79.0% adjusted, compared to 80.2% in the same period last year.&nbsp;
The fourth-quarter operating profit margin of 22.6%, or 25.6% adjusted, was in line with the company&#8217;s expectations.
&#8220;We exited the year in a strong position with three important growth drivers: TAVR, Mitral and Tricuspid, and two emerging opportunities in Structural Heart Failure and Aortic Regurgitation,&#8221; said Bernard Zovighian, Edwards&#8217; CEO. &#8220;In 2025, we expect to build on many catalysts across our businesses that will contribute to growth,&#8221; said Bernard Zovighian, Edwards&#8217; CEO.
Guidance: Edwards Lifesciences expects first quarter 2025 adjusted EPS of 58-64 cents versus the consensus of 59 cents and revenue of $1.35 billion—$1.43 billion versus the consensus of $1.412 billion.
Edwards&#8217; guidance for 2025 adjusted operating margins is 27%-28%, with annual operating profit margin expansion thereafter.
William Blair analyst Margaret Kaczor acknowledges that while Edwards Lifesciences&#8217; TAVR growth has potential, more evidence is needed to confirm it will reach the high end of 2025 guidance beyond Q1.
The analyst expects inefficiencies in catheter lab workflows to be temporary and believes long-term growth remains strong, particularly with the expansion of asymptomatic and moderate-risk indications over the next two years.
Meanwhile, continued strength in TMTT supports Edwards&#8217; market position and growth, with upcoming data and new product launches as potential catalysts.
Kaczor sees Edwards as a company with high-single- to low-double-digit sales growth, driven by increasing adoption in underpenetrated markets, structural heart expansion, and patient activation efforts to improve treatment access.
William Blair <a target="_blank" href="https://www.benzinga.com/quote/GILD/analyst-ratings" rel="noreferrer noopener">reiterates the Outperform rating</a>.
Price Action: EW stock is up 6.19% at $75.30 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43657775/sonic-automotive-beats-q4-estimates-grows-technician-workforce-for-2025" target="_blank" rel="noreferrer noopener">Sonic Automotive Beats Q4 Estimates, Grows Technician Workforce For 2025</a></li>
</ul>

Analyst Color

Earnings

Guidance

Movers

Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by <a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes">midday trading in New York.</a>
The S&amp;P 500 was down 0.2%, while the Nasdaq 100 was flat, both rebounding from sharp declines following the January Consumer Price Index report. Small-cap stocks underperformed, with the Russell 2000 slipping 0.8%.
The headline CPI rose 3% year over year in January, surpassing both December's 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December's 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Core inflation, which excludes food and energy, climbed to 3.3% year over year from 3.2% in December. On a monthly basis, core CPI increased 0.4%, exceeding estimates of 0.3% and doubling December's 0.2% rise.
Treasuries and interest rate markets reacted sharply to the inflation data. Traders scaled back expectations for Federal Reserve rate cuts, now projecting only one reduction by December 2025.
Treasury yields surged, reflecting heightened investor uncertainty. The 10-year Treasury yield jumped 10 basis points to 4.64%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 1%.
Despite rising Treasury yields and a stronger dollar, gold edged up 0.2% to $2,910 per ounce. Oil prices dropped 2% after reports that Donald Trump spoke with Russian President Vladimir Putin, fueling speculation about a potential ceasefire in Ukraine.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also rebounded from earlier session losses.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,688.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,056.85</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,411.00</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% down to $603.77.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.4% down to $444.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $528.09.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.8% to $224.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.4%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.2%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped more than 4% after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.</li>
</ul>
Stocks reacting to company earnings reports included: 
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 15.7%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): up 4.5%</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 5.6%</li>
<li>América Móvil, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>): down 1.4%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>): up 0.2%</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>): up 0.3%</li>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>): up 2.9%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): up 6.8%</li>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>): down 10.2%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): up 2.2%</li>
<li>Chimera Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>): down 8.9%</li>
<li>Ryder System Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>): up 4.0%</li>
<li>Smurfit WestRock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>): down 5.8%</li>
<li>Sonic Automotive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>): down 2.4%</li>
<li>Alkermes Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>): up 4.1%</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>): up 1.0%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>): down 4.6%</li>
<li>Blackstone Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>): up 2.8%</li>
<li>Camtek Ltd/Israel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>): up 1.5%</li>
<li>Chefs' Warehouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>): up 13.0%</li>
<li>Diebold Nixdorf Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>): down 3.2%</li>
<li>Dominion Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.6%</li>
<li>Exelon Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): up 0.4%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43663963/record-high-egg-prices-drive-inflation-higher-in-january">Record-High Egg Prices Drive Inflation Higher In January</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

ALKS

AVXL

BIIB

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

RBC Capital analyst Shagun Singh reiterates Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Outperform and maintains $85 price target.

Reiteration

RBC Capital Reiterates Outperform on Edwards Lifesciences, Maintains $85 Price Target

Piper Sandler analyst Adam Maeder maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and raises the price target from $70 to $73.

Piper Sandler Maintains Neutral on Edwards Lifesciences, Raises Price Target to $73

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a In-Line and lowers the price target from $75 to $73.

Evercore ISI Group Maintains In-Line on Edwards Lifesciences, Lowers Price Target to $73

WIIM

Edwards Lifesciences shares are trading higher after Morgan Stanley raised its price target on the stock from $70 to $75.

Morgan Stanley analyst Patrick Wood maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Equal-Weight and raises the price target from $70 to $75.

Morgan Stanley Maintains Equal-Weight on Edwards Lifesciences, Raises Price Target to $75

Edwards Lifesciences shares are trading higher following a Q4 earnings beat.

Edwards Lifesciences Sees Q1 Adj. EPS $0.58-$0.64 vs. $0.59 Est., Revenue $1.35B-$1.43B vs. $1.412B Est.

Earnings Beats

Edwards Lifesciences Q4 2024 Adj. EPS $0.59 Beats $0.55 Estimate, Sales $1.39B Beat $1.358B Estimate

U.S. stocks edged marginally lower on Tuesday after Federal Reserve Chair Jerome Powell reiterated that the central bank is in no hurry to cut interest rates during his testimony before the Senate Banking Committee, offering little <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43628752/feds-powell-reiterates-no-hurry-to-cut-interest-rates-as-inflation-remains-somewhat-elevated">support for risk assets.</a>
Investors remained on edge ahead of Wednesday's key inflation report, with the Bureau of Labor Statistics set to release the January Consumer Price Index.
The S&amp;P 500 dipped 0.1%, the Nasdaq 100 declined 0.2%, and small-cap stocks underperformed. Bucking the trend, the Dow Jones Industrial Average posted a marginal 0.1% gain.
Company-wise, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) surged 7%, after Vice President J.D. Vance indicated that artificial intelligence chips will be manufactured in the U.S.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell by over 4%, reaching the lowest levels in eleven weeks, pressured by weak January auto sales in China.
Geopolitical tensions flared as the European Union threatened countermeasures in response to President Donald Trump's announcement of 25% tariffs on aluminum and steel.
Long-dated Treasury yields moved higher, with the 10-year yield rising to 4.54%. Yet, the broader dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – weakened, down 0.2%. 
Gold paused for a breather, remaining flat at $2,900 per ounce. Oil prices inched up by 1%, eyeing the third straight session of gains. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) weakened 1.3% to $96,000. 
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,526.92</td>
<td>0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,064.30</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,714.53</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,273.29</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.1% down to $604.07.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.1% up to $445.06.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.3% to $527.55.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.7% to $225.34.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.4%; the&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) rose 2.4% after KeyBanc raised the stock to Overweight.</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) surged 5% after Elliott Investment Management urged the company to sell or spin off its midstream business, estimating its value at over $40 billion.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) gained 2.8%, and Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 2% amid speculation about a potential AI partnership for iPhone users in China.</li>
</ul>
Stocks reacting to earnings reports include: 
<ul>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 3.8%</li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 7.5%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 3.7%</li>
<li>DuPont de Nemours Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>): up 7.8%</li>
<li>Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>): down 5.6%</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>): down 6.5%</li>
<li>Masco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): up 0.6%</li>
<li>WK Kellogg Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>): down 0.7%</li>
<li>Arvinas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>): down 6.3%</li>
<li>AutoNation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>): down 3.3%</li>
<li>Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>): down 4.7%</li>
<li>Carrier Global Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 1.8%</li>
<li>Fidelity National Information Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>): down 14.9%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>): up 6.2%</li>
<li>IPG Photonics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>): down 5.9%</li>
<li>LCI Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>): up 3.5%</li>
<li>Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>): down 5.4%</li>
<li>MYT Netherlands Parent BV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>): up 19.4%</li>
<li>NNN REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>): up 5.8%</li>
<li>Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>): up 1.4%</li>
<li>Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>): down 1.8%</li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>): down 3.5%</li>
<li>USA Compression Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>): down 2.9%</li>
<li>Wesco International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>): up 2.1%</li>
</ul>
Companies reporting after the close include:
<ul>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>)</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</li>
<li>Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>)</li>
<li>Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>)</li>
<li>Primerica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>)</li>
<li>Allison Transmission Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>)</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>)</li>
<li>Brighthouse Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>)</li>
<li>DoorDash Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NYSE">DASH</a>)</li>
<li>W. P. Carey Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>)</li>
<li>Agree Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>)</li>
<li>Red Rock Resorts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>)</li>
<li>Teradata Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>)</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43632327/steel-stocks-breakout-analyst-sees-bullish-setup-for-us-steel-nucor-steel-dynamics">Tariffs Drive Steel Stock Gains As Analyst Highlights Catalysts For Nucor, US Steel</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

AAPL

ALSN

ARVN

BABA

Brighthouse Financial, Inc. - Common Stock

CARR

DASH

INTC

IPGP

LCII

LDOS

MYTE

RPRX

SPGI

STLD

USAC

PowerShares DB US Dollar Index Bullish Fund

WELL

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?

Press Releases

Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW

Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025

EDWARDS LIFESCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL:  Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW

Edwards Lifesciences Reports Fourth Quarter Results

EDWARDS LIFESCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Lifesciences Corporation - EW

Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference

Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

Comments

Edwards Lifesciences

Actualités

Dernières nouvelles pour Edwards Lifesciences (NYSE:EW) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL